Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
Capricor Therapeutics (CAPR) Misses Q1 EPS by 7c
May 12, 2016 4:50 PM EDTCapricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.26), $0.07 worse than the analyst estimate of ($0.19).
Financial Outlook
Based on current operating plans, the Company expects that its existing cash, cash equivalents and marketable securities will fund its research and development programs and other operations... More



